ada-2026
2 stories tagged "ada-2026"
Metabolic & Weight
Lilly's triple agonist hit 30% weight loss. The glucagon bet is why.
Lilly's triple agonist hit nearly 30% weight loss at 104 weeks at ADA 2026. The glucagon bet is what makes retatrutide different from semaglutide and Mounjaro, and it's what makes the open safety signals different too.
Metabolic & WeightRetatrutide's Triple-Receptor Triumph Came With a One-in-Five Skin-Sensation Signal Nobody Wanted to Linger On
Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe